Document Detail

Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality.
MedLine Citation:
PMID:  23047361     Owner:  NLM     Status:  MEDLINE    
CONTEXT: Neurotensin regulates both satiety and breast cancer growth in the experimental setting, but little is known about its role in the development of breast cancer or cardiometabolic disease in humans.
OBJECTIVE: To test if fasting plasma concentration of a stable 117-amino acid fragment from the neurotensin precursor hormone proneurotensin is associated with development of diabetes mellitus, cardiovascular disease, breast cancer, and mortality.
DESIGN, SETTING, AND PARTICIPANTS: Proneurotensin was measured in plasma from 4632 fasting participants of the population-based Malmö Diet and Cancer Study baseline examination 1991-1994. Multivariate Cox proportional hazards models were used to relate baseline proneurotensin to first events and death during long-term follow-up until January 2009, with median follow-up ranging from 13.2 to 15.7 years depending on the disease.
MAIN OUTCOME MEASURES: Incident diabetes mellitus, cardiovascular disease, breast cancer, and mortality.
RESULTS: Overall, proneurotensin (hazard ratio [HR] per SD increment of log-transformed proneurotensin) was related to risk of incident diabetes (142 events; HR, 1.28; 95% CI, 1.09-1.50; P = .003), cardiovascular disease (519 events; HR, 1.17; 95% CI, 1.07-1.27; P < .001), and cardiovascular mortality (174 events; HR, 1.29; 95% CI, 1.12-1.49; P = .001) with a significant interaction between proneurotensin and sex (P < .001) on risk of cardiovascular disease. Exclusively in women, proneurotensin was related to incident diabetes (74 events; HR, 1.41; 95% CI, 1.12-1.77; P = .003), cardiovascular disease (224 events; HR, 1.33; 95% CI, 1.17-1.51; P < .001), breast cancer (123 events; HR, 1.44; 95% CI, 1.21-1.71; P < .001), total mortality (285 events; HR, 1.13; 95% CI, 1.01-1.27; P = .03), and cardiovascular mortality (75 events; HR, 1.50; 95% CI, 1.20-1.87; P < .001).
CONCLUSION: Fasting proneurotensin was significantly associated with the development of diabetes, cardiovascular disease, breast cancer, and with total and cardiovascular mortality.
Olle Melander; Alan S Maisel; Peter Almgren; Jonas Manjer; Mattias Belting; Bo Hedblad; Gunnar Engström; Ute Kilger; Peter Nilsson; Andreas Bergmann; Marju Orho-Melander
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA     Volume:  308     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-10     Completed Date:  2012-10-15     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1469-75     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / blood*,  mortality
Cardiovascular Diseases / blood*,  mortality
Cohort Studies
Diabetes Mellitus / blood*,  mortality
Middle Aged
Neurotensin / blood*
Odds Ratio
Protein Precursors / blood*
Sweden / epidemiology
Reg. No./Substance:
0/Protein Precursors; 0/proneurotensin; 39379-15-2/Neurotensin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of public reporting for percutaneous coronary intervention with utilization and outcomes...
Next Document:  Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune...